Harte Hanks, Inc.

NasdaqGM:HHS Aktierapport

Börsvärde: US$21.1m

Harte Hanks Framtida tillväxt

Future kriterier kontrolleras 0/6

Vi har för närvarande inte tillräcklig analytikertäckning för att förutsäga tillväxt och intäkter för Harte Hanks.

Viktig information

n/a

Tillväxttakt i vinsten

n/a

Tillväxttakt för EPS

Media vinsttillväxt33.5%
Intäkternas tillväxttaktn/a
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

None

Senast uppdateradn/a

Senaste uppdateringarna om framtida tillväxt

Recent updates

Analysartikel • Apr 15

Is Harte Hanks (NASDAQ:HHS) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysartikel • Dec 03

Improved Revenues Required Before Harte Hanks, Inc. (NASDAQ:HHS) Stock's 25% Jump Looks Justified

Harte Hanks, Inc. ( NASDAQ:HHS ) shares have had a really impressive month, gaining 25% after a shaky period...
Analysartikel • Nov 26

Returns At Harte Hanks (NASDAQ:HHS) Are On The Way Up

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysartikel • Jun 24

We're Hopeful That Harte Hanks (NASDAQ:HHS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • May 01

Investors Don't See Light At End Of Harte Hanks, Inc.'s (NASDAQ:HHS) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 0.2x Harte Hanks, Inc. ( NASDAQ:HHS ) is a stock worth...
Analysartikel • Jul 03

Investors Aren't Entirely Convinced By Harte Hanks, Inc.'s (NASDAQ:HHS) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Harte Hanks, Inc. ( NASDAQ:HHS ) is a stock worth...
Analysartikel • Nov 03

With EPS Growth And More, Harte Hanks (NASDAQ:HHS) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysartikel • Oct 13

Harte Hanks, Inc.'s (NASDAQ:HHS) Intrinsic Value Is Potentially 30% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Harte Hanks fair value estimate is US$7.36 Harte Hanks...
Analysartikel • Jun 08

Harte Hanks (NASDAQ:HHS) Is Experiencing Growth In Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysartikel • Mar 16

Should You Investigate Harte Hanks, Inc. (NASDAQ:HHS) At US$8.83?

Harte Hanks, Inc. ( NASDAQ:HHS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Analysartikel • Feb 22

Does Harte Hanks (NASDAQ:HHS) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysartikel • Dec 07

Are Investors Undervaluing Harte Hanks, Inc. (NASDAQ:HHS) By 22%?

How far off is Harte Hanks, Inc. ( NASDAQ:HHS ) from its intrinsic value? Using the most recent financial data, we'll...
Analysartikel • Oct 27

If EPS Growth Is Important To You, Harte Hanks (NASDAQ:HHS) Presents An Opportunity

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Seeking Alpha • Sep 27

Harte Hanks: Good Point To Start Accumulation Again (Technical Analysis)

Summary I've analyzed Harte Hanks' stock price action over the last 4 years and found a trading strategy that has worked well since the company's turnaround. The cumulative return of the strategy was 203.61%, which is 4.83 times more than a buy-and-hold strategy would bring. This strategy encourages the bulls to act again now. Taking into account the existing growth potential, the current valuation multiples cannot be described as too high in absolute terms, which supports the system's call to action. I think it makes sense to use the current trading signal for at least part of the desired amount - the AI algorithm draws above $12 per share by the end of January 2023. Thesis I've analyzed Harte Hanks' (HHS) stock price action over the last 4 years using TrendSpider Software and found a trading strategy that has worked well since the company's turnaround. The conclusions we can draw from backtesting are straightforward - the algorithm calls for buying HHS at the current level. The company's valuation after the recent sell-off offers enough potential to support this conclusion. Harte Hanks and my previous theses Harte Hanks, Inc. is a micro-cap company with a market capitalization of $75.88M at the time of this writing. It operates as a customer experience company in the US and internationally, dividing its operations into 3 segments: The Marketing Services segment delivers strategic planning, data strategy, performance analytics, creative development and execution, technology enablement, marketing automation, and database management; The Customer Care segment operates teleservice workstations in the United States, Asia, and Europe to provide advanced contact center solutions such as speech, voice and video chat, integrated voice response, analytics, social cloud monitoring, and web self-service; The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, and monitoring and tracking to support traditional and specialty mailings. Since my last call, the company has not provided any new financials. To understand what happened in the above segments in the last quarter, I would like to quote my last article, where I analyzed the fundamentals in more detail. Let us now turn to the company's recent earnings call to understand what management expects in Q3/Q4 2022 and perhaps 2023. As you may see, the above-mentioned decrease in total revenues is due to a sharp decline in the Customer Care segment, which is due to the expected discontinuation of projects related to COVID. However, according to the CEO, this segment is expected to return to higher demand from existing and new customers in Q3 2022 as the company onboards agents to support the premiere of House of the Dragon. As the margins of this segment have improved on a half-year basis (due to cost optimizations), I expect that we will see revenue growth as well as EBITDA and EPS growth (at roughly the same margin level) in Q3 2022 due to new demand. As for the Fulfillment & Logistics business, the company has exceeded its own margin expectations - EBITDA of sales is 13.5% in 2H 2022, significantly better than in 2H 2021. The consolidation of operations into the Kansas City and Boston facilities, which I mentioned in the last article, is bearing fruit - Harte Hanks has a rapidly growing customer base and order book, while the major competitors in this industry are suffering from the size of their operations. Margins for this HHS segment will most likely stop increasing - or even decrease slightly - due to the impact of consolidation, but we will most likely see a positive change again in Q3 2022 due to the new volume. The Marketing Services segment is currently facing temporary difficulties - as expected, customers' advertising budgets began to shrink due to uncertainty about the impending recession. However, HHS management remains optimistic, talking about a new partnership with a regional bank signed in Q2 2022. At the time, HHS' financial success allowed it to exceed EPS expectations by nearly 90% and show roughly expected revenue, according to TradingView: Tradingview, HHS My coverage began a month before that August report when I drew attention to the company's fairly strong growth against a backdrop of modest valuation. I was also taken with the planned sale of preferred stock - this was to simplify the company's capital structure, and the one-time cost of such disposal while maintaining a steady growth rate should have paid off very quickly. The stock was gaining momentum at that point, and after my initial call, HHS went up 50% in a few days. Then I looked at the price action and realized that HHS had moved too far away from all the major moving averages and the forwarding valuation multiples were no longer low enough to provoke a similar rise. Data by YCharts Therefore, I have downgraded the rating from "Strong Buy" to "Buy" and reminded everyone that mean reversion is inevitable in such cases. It has been 35 days since the last article was written and HHS has fallen from $17.22 to the current $10.74 - that is -37.63%. The reversion to the mean occurred against a backdrop of general market weakness - over the same period, the S&P 500 Index fell 11.44%. So, given HHS's micro market capitalization, it's not surprising that momentum has changed so quickly. So what about now? As the stock continued to fall, I was repeatedly asked in the comments when HHS would return to the buy zone. Even long-term investors do not want to see big unrealized losses, even if they are convinced of the company's fundamental prospects, so technical analysis becomes as important as fundamental analysis. Since the company has not yet released financials (the Q3 report will be available on November 11) and the recent news about the partnership with FEVO is difficult to quantify, this time I decided to spend more time analyzing price action. I have included the data for the last 4 years - this is the period that has become a turning point for the company. Before that, Harte Hanks had problems with debt, with corporate development strategy. When new management came in and new initiatives emerged that led to a revitalization of the business, HHS stock price began to recover quickly - this just happened in the last 4 years. Considering today's oversold conditions (RSI below 30), I wonder if the current extremely low levels of the RSI are a sufficient argument for buying HHS. But to check that, you have to base the criterion for exiting a position - why not focus on the RSI again? For the exit, I chose the other extreme of this indicator - an extremely overbought RSI level of 75 and higher (I remind you that theoretically the stock is already considered overbought at the RSI >70). After analyzing the last 4 years, TrendSpider's backtesting system has produced the following results when applying the strategy described above: Data Analyzed 4 years Net Profit 203.61% Asset Perf. 42.18% Beta (vs Asset) 1.62 Positions 5 Wins 80% Losses 20% Max Drawdown -71.63% Average Win 50.78% Average Loss -27.45% Average Return 35.13% Rew/Risk Ratio 1.85 Expectancy 1.28 Source: TrendSpider, author's inputs That is, in the last 4 years, only 5 positions were opened, but despite the drawdown in one of them by 27.45% (holding period from October 2018 to September 2019), the cumulative return was 203.61%, which is 4.83 times more than a buy and hold strategy would bring. If we look at the behavior of the strategy, we find that the drawdown of the underlying was over ~85% since the start of the system testing, and the drawdown of the strategy was slightly better - about 71%: TrendSpider, HHS, Performance Chart The average trade opened below RSI 30 and closed above 75 earning the hypothetical investor an average of 35.13%, with the average position held open for about half a year. And what is most important for us now is that the 5th deal, which the system also takes into account in its calculations, was opened yesterday: TrendSpider, HHS
Analysartikel • Sep 19

Harte Hanks (NASDAQ:HHS) Could Become A Multi-Bagger

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...
Seeking Alpha • Sep 15

Harte Hanks and FEVO announce expanding partnership

Harte Hanks (NASDAQ:HHS) and FEVO, a social-commerce technology company that lets friends shop together, announced a growing partnership today. The partnership is designed to help FEVO maintain its fan-and client-first ethos, as FEVO builds upon its explosive growth from 2021. The partnership expands Harte Hanks' prior successful work with FEVO to now allow Harte Hanks to serve as FEVO's exclusive CX partner. "To enhance our customer experience as our consumer base continues to grow, we look forward to introducing Harte Hanks' services to FEVO partners in need." aid Betty Tran, FEVO CMO.
Seeking Alpha • Aug 23

Harte Hanks: Mean Reversion Imminent, But Still A Buy For Patient Investors

I am updating my thesis on Harte Hanks' stock and classifying it as a "Buy" instead of a "Strong Buy" as I did months ago. Harte Hanks' stock may soon go into reverse, but if you bought HHS with the desire to hold the stock for the long term, you definitely have nothing to worry about. I believe HHS will continue to grow operationally and provide great value to its investors going forward - the company is still cheap and making good progress in its turnaround. Long-term investors may soon have the opportunity to buy HHS cheaper, so I recommend keeping an eye on the stock. Intro & Thesis A little over a month ago, I initiated coverage of a small-cap marketing and customer experience company Harte Hanks, Inc. (HHS) and gave the stock a Strong Buy rating based on its high-quality fundamental profile, growth prospects, and low valuation. In just one month, my thesis has held up quite well, even compared to the July rally in the broader stock market: Seeking Alpha, my article on HHS [July 14] Since the publication of that article, the company has managed to report and hold an earnings call for analysts and investors. For this reason, I have decided to once again focus my attention and yours on HHS. Based on my updated analysis, I conclude that HHS, which has risen >50% in just 2 weeks, could face mean-reversion effects in the days ahead - especially if the S&P 500 (SPY) continues to correct below its 200-day moving average. However, if you bought HHS with the desire to hold the stock for the long term, you definitely have nothing to worry about - the valuation is still quite low, the turnaround is progressing, and the key fundamentals have only improved in Q2 2022. Therefore, I reiterate my buy recommendation, although I lower it from "Strong buy" given the high probability of a technical correction on the horizon. Why Do I Think So? For small-cap companies like HHS (market cap = $121 million), my observation is that fundamental changes within the company are more clearly reflected in stock prices. Either you grow and improve your business qualitatively (your stock starts to rise), or you lose - investors look at your capitalization and poor results and do not believe management's promises to fix everything when they fail, as is often the case with large technology companies, for example. That's why the extraordinary growth in HHS stock over the past year fits in with the company beating analysts' forecasts quarter after quarter: HHS Total Return Level data by YCharts Seeking Alpha, HHS, author's notes In the last reporting quarter (Q2 2022), Harte Hanks again managed to exceed analysts' expectations and deliver an EPS surprise of 89%. Revenue growth broke a number of positive surprises and was actually 1.5% lower than expected by the Street. However, as we all know very well, revenue is only the first key element of the income statement, but far from the last. Investors are interested in the profit and how the company copes with the tasks set for the turnaround - I talked about this in my last article. HHS's IR materials The business structure of the company is as follows: The Marketing Services segment delivers strategic planning, data strategy, performance analytics, creative development and execution, technology enablement, marketing automation, and database management; The Customer Care segment operates teleservice workstations in the United States, Asia, and Europe to provide advanced contact center solutions such as speech, voice and video chat, integrated voice response, analytics, social cloud monitoring, and web self-service; The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, and monitoring and tracking to support traditional and specialty mailings. Thus, despite the decline in sales in 2 of 3 segments, the company was able to increase its EBITDA growth to an impressive level by (its standards): HHS's recent 10-Q, author's notes Let us now turn to the company's recent earnings call to understand what management expects in Q3/Q4 2022 and perhaps 2023. As you may see, the above-mentioned decrease in total revenues is due to a sharp decline in the Customer Care segment, which is due to the expected discontinuation of projects related to COVID. However, according to the CEO, this segment is expected to return to higher demand from existing and new customers in Q3 2022 as the company onboards agents to support the premiere of House of the Dragon. As the margins of this segment have improved on a half-year basis (due to cost optimizations), I expect that we will see revenue growth as well as EBITDA and EPS growth (at roughly the same margin level) in Q3 2022 due to new demand. As for the Fulfillment & Logistics business, the company has exceeded its own margin expectations - EBITDA of sales is 13.5% in 2H 2022, significantly better than in 2H 2021. The consolidation of operations into the Kansas City and Boston facilities, which I mentioned in the last article, is bearing fruit - Harte Hanks has a rapidly growing customer base and order book, while the major competitors in this industry are suffering from the size of their operations. Margins for this HHS segment will most likely stop increasing - or even decrease slightly - due to the impact of consolidation, but we will most likely see a positive change again in Q3 2022 due to the new volume. The Marketing Services segment is currently facing temporary difficulties - as expected, customers' advertising budgets began to shrink due to uncertainty about the impending recession. However, HHS management remains optimistic, talking about a new partnership with a regional bank signed in Q2 2022. In addition, the company plans to complete the repurchase of preferred shares from Wipro (WIT) in Q3 2022 - this is a little tailwind for common shareholders for Q4, in my opinion. ... we reached an agreement with Wipro at the end of the quarter, in which we will acquire all of the outstanding preferred shares for a onetime cash payment of $9.9 million and 100,000 common stock shares. Please note that under GAAP at closing, this transaction will result in adjustments to our earnings per share but not our net income. This is likely to close during the third quarter. The elimination of the preferred stock dividend accrual and the earnings attributable to preferred shareholders will be offset by a onetime accounting charge based on the fair value of the common shares. We funded the cash portion of the repurchase consideration with a combination of cash and cash equivalents on hand and an additional $5 million borrowing under our credit facility. Source: HHS's earnings call According to YCharts, Harte Hanks generated nearly $8.5 million in free cash flow in 2Q2022, which is comparable only to the pre-crisis periods in which the company operated. Data by YCharts I believe that HHS will continue to grow operationally and provide great value to its investors in the future. Therefore, TTM FCF values should not be used as the sole benchmark for valuing a company as they are blind to the prospects. Why do I mention this? Because Seeking Alpha's Quant rating system shows that HHS's "Valuation" grade is "C+" while its price-to-cash flow ratio ((TTM)) is the only valuation factor of this quality in the sample. The other ratios are much better: Seeking Alpha, HHS, Valuation, author's notes
Analysartikel • Aug 13

Harte Hanks, Inc. (NASDAQ:HHS) Stock Catapults 25% Though Its Price And Business Still Lag The Market

Harte Hanks, Inc. ( NASDAQ:HHS ) shares have continued their recent momentum with a 25% gain in the last month alone...
Seeking Alpha • Aug 11

Harte Hanks GAAP EPS of $0.52 beats by $0.24, revenue of $48.6M misses by $0.7M

Harte Hanks press release (NASDAQ:HHS): Q2 GAAP EPS of $0.52 beats by $0.24. Revenue of $48.6M (-1.3% Y/Y) misses by $0.7M.
Analysartikel • Jul 26

What Does Harte Hanks, Inc.'s (NASDAQ:HHS) Share Price Indicate?

Harte Hanks, Inc. ( NASDAQ:HHS ), might not be a large cap stock, but it received a lot of attention from a substantial...
Seeking Alpha • Jul 14

Harte Hanks: This Top-Rated Micro-Cap Stock Has A Great Growth Potential

In my view, Harte Hanks Inc. is a classic example of a business turnaround that can reward investors over the long run. The financial and operational results show a qualitative improvement quarter-on-quarter due to the improved fully integrated business model. By buying HHS at current prices, it is unlikely that you will overpay for this growth opportunity - the valuation still looks cheap after the recent bullish rally. As the turnaround progresses, HHS's P/E ratio should nearly double once the company reaches the 2000-2012 scale. I recommend buying HHS stock today for the long term. Investment Thesis In my view, Harte Hanks Inc. (HHS) is a classic example of a turnaround - over the past decade the stock has fallen dozens of times in the face of deteriorating financial performance, but now things are turning for the better. The financial and operational results show a qualitative improvement quarter-on-quarter due to the improved fully integrated business model. That's why I am drawing investors' attention to this stock - with a relatively small market cap, HHS can grow many times over in the coming years, and by entering at the current price level, you will not have to pay too much for this growth opportunity. Why do I think so? Harte Hanks Inc. is a marketing and customer experience company with a market cap of just $86 million that has delivered phenomenal returns since the beginning of 2022. Especially when we compare it to the major indices: Data by YCharts Such a strong performance against a declining market was possible thanks to phenomenal operating results. Author's calculations, SA data In recent quarters, HHS has managed to move from negative to positive growth, both in sales and in gross profit and EBITDA. Thanks to the optimization of fixed costs - D&A and SG&A have been decreasing quarterly by an average of 1.8% and 6.8%, respectively, since Q3 2019 - EBITDA has grown by a multiple of gross profit growth. To better understand how the company manages to optimize costs so effectively against a backdrop of double-digit revenue growth (TTM revenue is up ~11% year-over-year), I recommend you take a look at the company's business structure. Harte Hanks divides its operations into 3 segments [Source: HHS's most recent 10-Q]: The Marketing Services segment delivers strategic planning, data strategy, performance analytics, creative development and execution, technology enablement, marketing automation, and database management; The Customer Care segment operates teleservice workstations in the United States, Asia, and Europe to provide advanced contact center solutions such as speech, voice and video chat, integrated voice response, analytics, social cloud monitoring, and web self-service; The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, and monitoring and tracking to support traditional and specialty mailings. If you look at functionality, you can think of the company's activities as two services - one marketing and one operational: Harte Hanks' IR materials These activities are intertwined upon closer inspection - in my view, the Fulfillment & Logistics Services segment is particularly well positioned to effectively solve the supply chain problems of the company's customers, thanks to HHS's technological developments in data analytics. In other words, a kind of synergy effect is forming in an inconspicuous area that has experienced bottlenecks in recent years and is of great importance for the economic growth not only of individual regions but of the entire world. The CEO devoted a lot of time during the most recent earnings call to examples of how the company's fully integrated business model helps partners and customers achieve greater agility in their operations. A notable example is the success of the recent consolidation of the Kansas City facility, which had been restructured in recent years. Now the restructuring is complete - meaning that a significant portion of the costs that have been weighing on the company's income statement will no longer be relevant. HHS's IR materials, author's notes Yes, there is a low base effect due to past restructuring spending - earnings were temporarily understated and triple-digit EBITDA growth rates appear to be durable, although this effect is likely to fizzle out in a few quarters. But even without taking into account the effect of eliminating the restructuring, the company can grow organically - as shown by the margin expansions in the various business segments, which are presented without the impact of this type of expenditure. Author's calculations, based on HHS's 10-Q The latest corporate news can only rejoice in management's desire to get rid of preferred stock. The Preferred Shares will be repurchased in exchange for ((i)) a cash payment equal to their liquidation value, or $9,926,000 and ((ii)) 100,000 shares of Harte Hanks common stock. The Preferred Shares to be repurchased are currently convertible into approximately 16% of the Company's common stock on a fully diluted basis. Harte Hanks will fund the cash portion of the repurchase consideration with a combination of cash and cash equivalents on hand and borrowings under the Company's credit facility. The repurchase is expected to close by the end of the third quarter of 2022. Source: Harte Hanks' press release Over the last 4 quarters, distributions to preferred shareholders have gobbled up an average of 15.5% of quarterly net income - getting rid of this expense item now can significantly increase the company's prospect value to common shareholders. As the company expands, the growth of the company will slow down. Therefore, we must evaluate everything that can affect the quality of this growth (gross profit, EBITDA, etc.). We already know that the company will liquidate preferred shares at the expense of its own cash (about $9.7 million at the end of March 2022) and a new credit facility - which will increase net income and earnings per share by about 15% from the end of 2022 to the end of 2023 and could support net income numbers going forward. What the cash to debt ratio will be in this transaction is not yet known, but the company's current coverage ratio (TTM Times-Interest-Earned ratio = ~26) allows for a slight increase in debt without any problems. No new restructuring is planned (I have not found any such information. If you know more, feel free to share your insights in the comment section below). Therefore, even with a slight increase in the customer base or an expansion of relationships with the existing customer base, Harte Hanks will very likely be able to again exceed what I believe are underestimated analyst expectations: Seeking Alpha, HHS, Earnings Summary data Note: the EPS consensus forecast for Q3 2022 appears to include a planned buyout of preferred shares. The current Harte Hanks looks nothing like what we saw a few years ago - one of the slides in the company's June IR presentation says it best: HHS's IR presentation
Seeking Alpha • May 23

Harte-Hanks: Deep Valuation And Future Growth Could Double The Stock

Harte-Hanks trades with an attractively low forward valuation. Harte-Hanks is expected to achieve earnings growth in 2023, while many companies are projecting earnings declines. The low valuation and projected growth leaves a one-year target price that is more than double the current price.

I detta avsnitt presenterar vi vanligtvis intäkts- och vinsttillväxtprognoser baserade på professionella analytikers konsensusuppskattningar för att hjälpa investerare att förstå företagets förmåga att generera vinst. Men eftersom Harte Hanks inte har tillhandahållit tillräckligt med tidigare data och inte har någon analytikerprognos kan dess framtida resultat inte beräknas på ett tillförlitligt sätt genom att extrapolera tidigare data eller använda analytikerförutsägelser.

Detta är en ganska sällsynt situation eftersom 97% av de företag som omfattas av SimplyWall St har tidigare finansiella uppgifter.

Prognoser för vinst- och omsättningstillväxt

NasdaqGM:HHS - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/2025160-1-4-2N/A
9/30/2025167-502N/A
6/30/2025175-3-7-5N/A
3/31/2025181-31-12N/A
12/31/2024185-30-7-3N/A
9/30/2024188-30-7-3N/A
6/30/2024187-29-12N/A
3/31/2024190-103N/A
12/31/2023191-2810N/A
9/30/2023197231113N/A
6/30/2023204292024N/A
3/31/2023204322631N/A
12/31/2022206352329N/A
9/30/2022203142026N/A
6/30/202219912713N/A
3/31/202220017-13N/A
12/31/202119513-5-2N/A
9/30/202119012-6-2N/A
6/30/20211887-9-5N/A
3/31/2021180-8-12-10N/A
12/31/2020177-2-11-8N/A
9/30/2020182-6-11-9N/A
6/30/2020186-11-12-11N/A
3/31/2020199-9811N/A
12/31/2019218-27912N/A
9/30/2019235-22N/A7N/A
6/30/2019248-26N/A4N/A
3/31/2019263-28N/A-15N/A
12/31/201828515N/A-9N/A
9/30/2018314-16N/A4N/A
6/30/2018345-8N/A14N/A
3/31/2018370-5N/A-27N/A
12/31/2017384-42N/A-31N/A
9/30/2017394-85N/A-54N/A
6/30/2017397-86N/A-49N/A
3/31/2017400-90N/A9N/A
12/31/2016404-90N/A15N/A
9/30/2016411-18N/A32N/A
6/30/2016423-188N/A28N/A
3/31/2016434-187N/A18N/A
12/31/2015444-181N/A33N/A
9/30/2015474-170N/A36N/A
6/30/20154999N/A41N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: Otillräcklig data för att avgöra om HHS s prognostiserade vinsttillväxt ligger över sparkvoten ( 3.5% ).

Resultat vs marknad: Otillräcklig data för att avgöra om HHS s intäkter förväntas växa snabbare än marknaden för US

Höga tillväxtresultat: Otillräcklig data för att avgöra om HHS s intäkter förväntas växa avsevärt under de kommande 3 åren.

Intäkt vs marknad: Otillräcklig data för att avgöra om HHS s intäkter förväntas växa snabbare än marknaden för US.

Hög tillväxtintäkter: Otillräcklig data för att avgöra om intäkterna från HHS förväntas växa snabbare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om HHS s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/07 01:31
Aktiekurs vid dagens slut2026/05/07 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Harte Hanks, Inc. bevakas av 7 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Daniel LebenBaird
Edward AtorinoBenchmark Company
Daniel SalmonBMO Capital Markets Equity Research